<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Background/Aims: Systemic <z:mp ids='MP_0001845'>inflammatory responses</z:mp> have been reported to be independent predictors of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>-specific survival in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>The Glasgow Prognostic Score (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GPS</z:e>), which is an <z:mp ids='MP_0001845'>inflammation</z:mp>-based prognostic factor, is defined by the presence of elevated C-reactive protein and <z:hpo ids='HP_0003073'>hypoalbuminemia</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>The purpose of this study was to estimate whether <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GPS</z:e> can be a prognostic factor in patients undergoing curative surgery for <z:e sem="disease" ids="C1527249" disease_type="Neoplastic Process" abbrv="">colorectal cancers</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Methods: We studied 166 patients with stage II (TNM classification) and 200 patients with stage III who had undergone curative surgery for <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> between 1999 and 2004 </plain></SENT>
<SENT sid="4" pm="."><plain>Univariate and multivariate analyses were performed to evaluate the relationship between clinicopathological factors and prognosis </plain></SENT>
<SENT sid="5" pm="."><plain>Results: Among patients with stage II, location and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GPS</z:e> were independent factors on multivariate analysis </plain></SENT>
<SENT sid="6" pm="."><plain>In particular, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GPS</z:e> was revealed to be the strongest factor in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>-specific survival (HR: 7.43, 95% confidence interval, CI: 2.86-19.30, p &lt; 0.0001) </plain></SENT>
<SENT sid="7" pm="."><plain>On the other hand, among patients with stage III, the number of metastatic lymph nodes was the only independent factor on multivariate analysis (HR: 1.14, 95% CI: 1.07-1.20, p &lt; 0.0001) </plain></SENT>
<SENT sid="8" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GPS</z:e> was not a prognostic factor in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>-specific survival in stage III </plain></SENT>
<SENT sid="9" pm="."><plain>Conclusion: Among patients with stage II, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GPS</z:e> was predictive of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>-specific survival </plain></SENT>
</text></document>